A5014683696- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Pulmonary Hypertension Research and Treatments
- Aortic Disease and Treatment Approaches
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Function and Risk Factors
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrhythmias and Treatments
- Transplantation: Methods and Outcomes
- Peripheral Artery Disease Management
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Issues in Pregnancy
- Chronic Kidney Disease and Diabetes
- Kawasaki Disease and Coronary Complications
- Cardiac Arrest and Resuscitation
- Vascular Anomalies and Treatments
- Cardiac and Coronary Surgery Techniques
University of Bologna
2016-2025
Policlinico S.Orsola-Malpighi
2015-2025
Azienda USL di Bologna
2021-2025
ERN GUARD-Heart
2024
Ospedale Santa Maria Goretti
2023
Azienda Ospedaliera San Giovanni Addolorata
2023
Agostino Gemelli University Polyclinic
2023
Azienda Ospedaliera G. Brotzu
2023
Centro Cardiologico Monzino
2023
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele
2023
Abstract Aims The CLIMA study, on the relationship between coronary plaque morphology of left anterior descending artery and twelve months clinical outcome, was designed to explore predictive value multiple high-risk features in same lesion [minimum lumen area (MLA), fibrous cap thickness (FCT), lipid arc circumferential extension, presence optical coherence tomography (OCT)-defined macrophages] as detected by OCT. Composite cardiac death target segment myocardial infarction primary...
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a heterogeneous entity relevant long-term major cardiovascular events. Several trials have demonstrated that dual antiplatelet therapy (DAPT), β-blocker, renin-angiotensin-aldosterone system (RAAS) inhibitor and statin improve the prognosis in patients obstructive myocardial (ob-MI). However, evidence on best medical for secondary prevention MINOCA lacking.
The introduction of transcatheter aortic valve implantation (TAVI) has generated a renewed interest in the treatment high-risk patients with severe stenosis. This study describes indications and long-term outcome balloon valvuloplasty (BAV) recent years.Between 2000 2010, 415 consecutive at our institution underwent BAV. number BAV per year increased sharply after TAVI. Patients were 77.5±10.9 years old showed important comorbidities (average logistic EuroSCORE=23.9±15.3%). We identified...
New conduction disturbances are frequent after transcatheter aortic valve implantation (TAVI). Refining our ability to predict high-grade atrioventricular block (AVB) occurring later than 24 hours the procedure would be useful in order select patients eligible for early discharge.
Aims Treatment delay is a powerful predictor of survival in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). We investigated effectiveness pre-hospital diagnosis STEMI with direct referral to PCI, alongside more conventional strategies.
Many inoperable patients with severe aortic stenosis (AS) are not immediately eligible for transcatheter valve implantation (TAVI). We evaluated the role of percutaneous balloon valvuloplasty (BAV) in this setting.Among 210 consecutive referred to our institution BAV, we identified three groups: TAVI (n=65, 31%), excluded from (n=67, 32%), BAV as a bridge (n=78, 37%). This last group comprised low left ventricular ejection fraction, frailty or enfeebled status, symptoms uncertain origin,...
Randomized trials showed that mTOR inhibitors prevent early development of cardiac allograft vasculopathy (CAV). However, the action these drugs on CAV late after transplant is controversial, and their effectiveness for prevention in clinical practice poorly explored. In this observational study we included 143 consecutive heart recipients who underwent serial intravascular ultrasound (IVUS), receiving either everolimus or mycophenolate as adjunctive therapy to cyclosporine. Ninety-one...
Objectives Assess clinical consequences of acute stent malapposition (ASM) in the context multicenter Centro per la Lotta Contro l'Infarto‐Optimization Percutaneous Coronary Intervention (CLI‐OPCI) registry. Background ASM as important determinant thrombosis (ST) risk remains controversial. Methods From 2009 to 2013, we retrospectively analyzed postprocedural optical coherence tomography (OCT) findings 864 patients undergoing percutaneous coronary intervention, assessing prevalence and...
<h3>Objective:</h3> To assess the clinical impact of a regional network for treatment ST-segment elevation myocardial infarction (STEMI). <h3>Methods:</h3> All patients with STEMI (n = 1823) admitted to any hospitals an area one million inhabitants during year 2002 858)—that is, before was implemented, and in 2004 965), full implementation network, were enrolled this study. The primary evaluation in-hospital mortality. Secondary outcomes included incidence major adverse cardiac...
To evaluate the clinical impact of early administration glycoprotein IIb/IIIa agents (IIb/IIIa agents) in context a dedicated hub and spoke network allowing very prompt pharmacological/mechanical interventions. Using prospective database, we conducted cohort study ST-elevation myocardial infarction (STEMI) patients ( n = 1124) undergoing primary percutaneous coronary interventions (PPCIs) (period, 2003–2006). Comparisons were planned between receiving (in hub/spoke centre emergency...
To test the equivalence of high-dose bolus (HDB) tirofiban vs. abciximab during primary percutaneous coronary intervention (PPCI) in terms ST-segment resolution (STR). The FATA trial (Facilitated Angioplasty with Tirofiban or Abciximab) was a prospective, multicentre, open-label that enrolled 692 patients elevation myocardial infarction (STEMI) undergoing PPCI. Patients were randomized 1:1 to receive (n = 341) HDB 351). Primary endpoint rate complete (≥70%) STR 90 min after first balloon...
Summary Mean platelet volume (MPV) has been proposed as a marker of reactivity and cardiovascular risk. Its prognostic significance not thoroughly investigated in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). We included 1,041 consecutive NSTE-ACS. Patients were divided quartiles according to the MPV value on admission (fl) i.e. Q1<7.5; Q2=7.5–8.0; Q3=8.1–8.8; Q4≥8.9. The primary study endpoint was composite death re-myocardial infarction (MI) at one year. Secondary...
To ascertain incidence and predictors of new permanent pacemaker (PPM) following transcatheter aortic valve implantation (TAVI) with the self-expanding bioprosthesis.TAVI Medtronic Corevalve (MCV) Revalving System (Medtronic, Minneapolis, MN) has been associated important post-procedural conduction abnormalities frequent need for PPM.Overall, 73 consecutive patients severe symptomatic AS underwent TAVI MCV at two institutions; 10 previous 3 replacement were excluded this analysis. Clinical,...